The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria
Zuberbier, T; Abdul Hameed Ansari, Z; Abdul Latiff, A H; Abuzakouk, M M; Agcaoili-De Jesus, M S; Agondi, R C; Al-Ahmad, M; Alangari, A A; Alhameli, H; Alonso Bello, C D; Alshareef, S; Al-Tamemi, S; Altrichter, S; Al Wahshi, H; Aquilina, S; Araújo, M; Arnaout, R; Asero, R; Ballmer-Weber, B; Bangert, C; Bauer, A; Ben-Shoshan, M; Bernstein, J; Bindslev-Jensen, C; Bizjak, M; Boccon-Gibod, I; Bonnekoh, H; Bouillet, L; Brockow, K; Brzoza, Z; Bulatović Ćalasan, M; Bulkhi, A; Buttgereit, T; Bygum, A; Caballero, T; Calderon, O; Campos, R; Cancian, M; Carne, E; Castor, M A; Cerecedo, I; Çetinarslan, T; Cherrez-Ojeda, I; Chkhikvadze, N; Chong-Neto, H J; Choo, K; Christoff, G; Chu, C-Y; Ciupka, K; Conlon, N; Costa, C; Craig, T; Criado, P; Danilycheva, I; Darlenski, R; De Arruda Chaves, E; de Montjoye, L; Doutre, M S; Du-Thanh, A; Ebo, D; Elkhalifa, S; Elmariah, S; El-Shanawany, T; Ensina, L F; Ertaş, R; Fachini Jardim Criado, R; Ferrer, M; Ferrucci, S; Fok, J S; Fomina, D; Fonacier, L; Fouda, G; Francescantonio, I; Fukunaga, A; Galvan Calle, C A; Garcia, E; Gáspár, K; Gelincik, A; Geng, S; Godse, K; Gonçalo, M; Gotua, M; Grattan, C; Grosber, M; Guidos Fogelbach, G; Guilarte, M; Guillod, R; Hamelmann, E; Hawkes, J; Hayama, K; Heuer, R; Hide, M; Hoetzenecker, W; Inomata, N; Kang, H-R; Kaplan, A; Kapp, A; Karam, M; Kasperska-Zajac, A; Katelaris, C H; Kessel, A; Khoshkhui, M; Kim, B; Kinaciyan, T; Kocatürk, E; Kolacinska-Flont, M; Kolkhir, P; Konstantinou, G N; Kosnik, M; Krasowska, D; Kulthanan, K; Kumaran, M S; Kuprys-Lipinska, I; Labrador, M; Larco, J I; Larenas-Linnemann, D; Latysheva, E; Lazaridou, E; Li, P H; Lima, H; Lippert, U; Magerl, M; Makris, M; Alves Marcelino, J; Marzano, A V; Medina, I; Meshkova, R; Micallef, D; Mohammed Ali, R; Mortz, C G; Munoz, M; Oude Elberink, H N G; Nakonechna, A; Nasr, I; Nast, A; Netchiporouk, E; Nettis, E; Nieto, S; Ogueta Canales, I; Okas, T-L; Orfali, R L; Özkaya, E; Parisi, C; Pennitz, A; Pawankar, R; Pereira, M P; Peter, J; Petkova, E; Pigatto, P D; Podder, I; Popov, T; Porebski, G; Pyatilova, P; Ramon, G D; Ratti Sisa, H A; Recto, M; Ress, K; Ridge, K; Riedl, M; Ritchie, C; Rosario Filho, N; Rosmaninho, I; Rudenko, M; Rukhadze, M; Rutkowski, K; Sabato, V; Sahiner, U M; Saini, S; Saleh Al Sabbagh, F; Salman, A; Salvo, F; Sanchez, J; Santucci, A; Schliemann, S; Schmid-Grendelmeier, P; Sekerel, B E; Serpa, F; Sheikh, F; Sheikh, J; Shendi, H; Siebenhaar, F; Sonomjamts, M; Soria, A; Sousa Pinto, B; Staevska, M; Staubach, P; Stephan, M; Stevanovic, K; Stingeni, L; Stobiecki, M; Su Küçük, Ö; Sussman, G; Szegedi, A; Takahagi, S; Tanaka, A; Teovska Mitrevska, N; Thomsen, S F; Toubi, E; Tsatsou, F; Turk, M; Vadasz, Z; Valerieva, A; Valle, S; Doorn, M V; Veleiro Perez, B; Vera Ayala, C E; Vestergaard, C; Vieira, R J; Maruta, C W; Wedi, B; Werner, R N; Yap, E W Y; Xepapadaki, P; Xiang, Y; Ye, Y-M; Yong, P; Yosipovitch, G; Zalewska-Janowska, A Z J; Zeyen, C; Zhao, Z; Metz, M; Giménez-Arnau, A M
This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), with the participation of 210 delegates from 107 national and international societies, from 59 countries. The consensus conference was held on December 6th, 2024. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease, defined by a rapid appearance of wheals, angioedema, or both. The lifetime prevalence of acute urticaria is estimated to be approximately 20%. Chronic urticaria, categorized as either chronic spontaneous urticaria or chronic inducible urticaria, is disabling, impairs quality of life, and affects performance at work and school, however, novel therapies are available. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.
PMID: 41649409
ISSN: 1398-9995
CID: 6000592
Disparities in diabetes treatment and monitoring for people with and without mental disorders: a systematic review and meta-analysis
Wagner, Elias; Højlund, Mikkel; Fiedorowicz, Jess G; Nielsen, René Ernst; Østergaard, Søren Dinesen; Høye, Anne; Heiberg, Ina H; Poddighe, Laura; Delogu, Marco; Holt, Richard I G; Correll, Christoph U; Cortese, Samuele; Carvalho, Andre F; Boyer, Laurent; Dragioti, Elena; Du Rietz, Ebba; Firth, Joseph; Fusar-Poli, Paolo; Hartman, Catharina A; Larsson, Henrik; De Giorgi, Riccardo; Lehto, Kelli; Lindgren, Peter; Manchia, Mirko; Nordentoft, Merete; Skonieczna-Żydecka, Karolina; Veroniki, Areti-Angeliki; Marx, Wolfgang; Campana, Mattia; Mortazavi, Matin; Hasan, Alkomiet; Stubbs, Brendon; Taipale, Heidi; Vancampfort, Davy; Vieta, Eduard; Solmi, Marco; ,
BACKGROUND:People with mental disorders have an increased risk of diabetes, yet conflicting evidence exists regarding the quality of diabetes care they receive. To address this evidence gap, we conducted a systematic review and meta-analysis to assess and compare diabetes quality of care in people with diabetes with mental disorders versus people with diabetes without mental disorders. METHODS:test, blood pressure measured, foot surveillance, serum creatinine test, serum cholesterol test, BMI recorded, smoking status recorded, retinal monitoring). Secondary outcomes were study-specific diabetes quality of care individual indicators matched to the nine NICE diabetes monitoring indicators and specific diabetes interventions and anti-diabetes medications. We analysed primary and secondary outcomes according to any mental disorder and to specific diagnostic subgroups. Study quality was evaluated using the Newcastle-Ottawa Scale (NOS). FINDINGS/RESULTS:measurement (24 studies, 0·81 [0·68-0·97], p=0·024), retinal screening (21 studies, 0·77 [0·63-0·95], p=0·013), lipid and cholesterol measurement (20 studies, 0·83 [0·69-0·99], p=0·043), foot examination (11 studies, 0·85 [0·76-0·95], p=0·0044), and renal investigation (16 studies, 0·78 [0·63-0·96], p=0·022). A significant positive association was found between any mental disorder and recorded smoking status (two studies, 1·09 [1·02-1·17]; p=0·0076). Any mental disorder was significantly associated with higher odds of receiving insulin (ten studies, 1·52 [95% CI 1·16-1·99]; p=0·0022), but negatively associated with treatment with a GLP-1 receptor agonist (two studies, 0·26 [0·13-0·49]; p<0·0001). There was no evidence of publication bias. INTERPRETATION/CONCLUSIONS:Mental disorders are negatively associated with receiving adequate diabetes monitoring and GLP-1 agonist therapy. Addressing these disparities has the potential to address the increased mortality associated with mental disorders. FUNDING/BACKGROUND:None.
PMID: 41506273
ISSN: 2215-0374
CID: 5981242